How to reconcile the advertising of medicinal products with the need to safeguard public health in the EU
This article was originally published in SRA
Executive Summary
Maria Isabel Manley and Maria Georgiou examine how the MSD Sharp & Dohme and Novo Nordisk cases will affect industry's ability to advertise its products.